NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype

被引:34
作者
Hasina, R
Pontier, AL
Fekete, MJ
Martin, LE
Qi, XM
Brigaudeau, C
Pramanik, R
Cline, EI
Coignet, LJ
Lingen, MW
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[4] Vet Affairs Edward Hines Jr Hosp, Maywood, IL USA
[5] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[6] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA
关键词
cervical cancer; nucleolus; tumor suppressor gene; angiogenesis; VEGF; TSP-1;
D O I
10.1038/sj.onc.1209070
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Cervical cancer is associated with human papilloma virus infection. However, this infection is insufficient to induce transformation and progression. Loss of heterozygosity analyses suggest the presence of a tumor suppressor gene (TSG) on chromosome 6p21.3-p25. Here we report the cloning NOL7, its mapping to chromosome band 6p23, and localization of the protein to the nucleolus. Fluorescence in situ hybridization analysis demonstrated an allelic loss of an NOL7 in cultured tumor cells and human tumor samples. Transfection of NOL7 into cervical carcinoma cells inhibited their growth in mouse xenografts, confirming its in vivo tumor suppressor activity. The induction of tumor dormancy correlated with an angiogenic switch caused by a decreased production of vascular endothelial growth factor and an increase in the production of the angiogenesis inhibitor thrombospondin-1. These data suggest that NOL7 may function as a TSG in part by modulating the expression of the angiogenic phenotype.
引用
收藏
页码:588 / 598
页数:11
相关论文
共 52 条
[1]
How tumors become angiogenic [J].
Bouck, N ;
Stellmach, V ;
Hsu, SC .
ADVANCES IN CANCER RESEARCH, VOL 69, 1996, 69 :135-174
[2]
Medical progress - Cancer of the uterine cervix [J].
Cannistra, SA ;
Niloff, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) :1030-1038
[3]
CHEN TM, 1993, CANCER RES, V53, P1167
[4]
Nonrandom rearrangements of 6p in malignant hematological disorders [J].
Chen, Z ;
Issa, B ;
Brothman, LJ ;
Hendricksen, M ;
Button, D ;
Brothman, AR .
CANCER GENETICS AND CYTOGENETICS, 2000, 121 (01) :22-25
[5]
Claudio PP, 2001, CANCER RES, V61, P462
[6]
Coignet LJA, 1999, GENE CHROMOSOME CANC, V25, P222, DOI 10.1002/(SICI)1098-2264(199907)25:3<222::AID-GCC4>3.0.CO
[7]
2-C
[8]
CONTROL OF ANGIOGENESIS IN FIBROBLASTS BY P53 REGULATION OF THROMBOSPONDIN-1 [J].
DAMERON, KM ;
VOLPERT, OV ;
TAINSKY, MA ;
BOUCK, N .
SCIENCE, 1994, 265 (5178) :1582-1584
[9]
The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun [J].
Dejong, V ;
Degeorges, A ;
Filleur, S ;
Ait-Si-Ali, S ;
Mettouchi, A ;
Bornstein, P ;
Binétruy, B ;
Cabon, F .
ONCOGENE, 1999, 18 (20) :3143-3151
[10]
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene [J].
Gnarra, JR ;
Zhou, SB ;
Merrill, MJ ;
Wagner, JR ;
Krumm, A ;
Papavassiliou, E ;
Oldfield, EH ;
Klausner, RD ;
Linehan, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :10589-10594